Immunocal® limits gliosis in mouse models of repetitive mild-moderate traumatic brain injury

• Published in: Brain research 2023-06, Vol.1808, p.148338-148338, Article 148338
• Main Authors: Koza, Lilia A., Pena, Claudia, Russell, Madison, Smith, Alec C., Molnar, Jacob, Devine, Maeve, Serkova, Natalie J., Linseman, Daniel A.
• Format: Article
• Language: English
• Subjects: Animals; Brain Concussion; Brain Injuries, Traumatic - complications; Dietary Supplements; Disease Models, Animal; Gliosis; Glutathione; Glutathione - metabolism; Mice; Neuroinflammation; Neuroprotection; Oxidative stress; Secondary injury; Traumatic brain injury
• ISSN: 0006-8993; 1872-6240
• DOI: 10.1016/j.brainres.2023.148338

[Display omitted] •Repetitive mTBI can induce lasting gliosis out to 2 months post-trauma.•Inflammation presents acutely following repetitive mild-moderate TBI.•The GSH precursor, Immunocal®, significantly limits gliosis in these models of mTBI.•Our findings show the limits of GSH-based neuroprotection in repetitive mTBI models. Successive traumatic brain injuries (TBIs) exacerbate neuroinflammation and oxidative stress. No therapeutics exist for populations at high risk of repetitive mild TBIs (rmTBIs). We explored the preventative therapeutic effects of Immunocal®, a cysteine-rich whey protein supplement and glutathione (GSH) precursor, following rmTBI and repetitive mild-moderate TBI (rmmTBI). Populations that suffer rmTBIs largely go undiagnosed and untreated; therefore, we first examined the potential therapeutic effect of Immunocal® long-term following rmTBI. Mice were treated with Immunocal® prior to, during, and following rmTBI induced by controlled cortical impact until analysis at 2 weeks, 2 months, and 6 months following the last rmTBI. Astrogliosis and microgliosis were measured in cortex at each time point and edema and macrophage infiltration by MRI were analyzed at 2 months post-rmTBI. Immunocal® significantly reduced astrogliosis at 2 weeks and 2 months post-rmTBI. Macrophage activation was observed at 2 months post-rmTBI but Immunocal® had no significant effect on this endpoint. We did not observe significant microgliosis or edema after rmTBI. The dosing regimen was repeated in mice subjected to rmmTBI; however, using this experimental paradigm, we examined the preventative therapeutic effects of Immunocal® at a much earlier timepoint because populations that suffer more severe rmmTBIs are more likely to receive acute diagnosis and treatment. Increases in astrogliosis, microgliosis, and serum neurofilament light (NfL), as well as reductions in the GSH:GSSG ratio, were observed 72 h post-rmmTBI. Immunocal® only significantly reduced microgliosis after rmmTBI. In summary, we report that astrogliosis persists for 2 months post-rmTBI and that inflammation, neuronal damage, and altered redox homeostasis present acutely following rmmTBI. Immunocal® significantly limited gliosis in these models; however, its neuroprotection was partially overwhelmed by repetitive injury. Treatments that modulate distinct aspects of TBI pathophysiology, used in combination with GSH precursors like Immunocal®, may show more protection in these repetitive TBI models